Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Trial Profile

Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Elagolix (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 20 Nov 2017 Planned End Date changed from 17 May 2019 to 29 Mar 2019.
    • 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Oct 2017 Planned End Date changed from 16 Jul 2019 to 17 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top